Valuation: Cognetivity Neurosciences Ltd.

Market Cap 1.2M 846K 744K 690K 635K 80.98M 1.22M 8.22M 3.22M 39.81M 3.18M 3.11M 138M P/E 2022
-2.9x
P/E 2023 -2.8x
Enterprise Value 245K 173K 152K 141K 130K 16.56M 251K 1.68M 658K 8.14M 651K 636K 28.13M EV / Sales 2022
-
EV / Sales 2023 437,922,999x
Free-Float
85.56%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 45 31/03/2013
Compliance Officer 67 20/12/2017
Director TitleAgeSince
Director/Board Member 45 31/12/2016
Director/Board Member 67 20/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-33.33% - - 93
+3.52%+2.11%-28.66%-4.83% 30.88B
+0.97%-5.09%-37.30%+211.69% 14.32B
+1.42%-3.18%-20.49%+72.53% 5.64B
-2.10%-6.45% - - 2.3B
+3.92%+8.48%+62.70%-36.36% 2.04B
-0.31%-17.98% - - 1.84B
-0.14%-4.46%-29.81% - 1.09B
-2.81%-4.21%+47.16%+105.51% 948M
-0.94%-0.26%-33.39%+250.15% 832M
Average +0.35%-3.86%-5.68%+99.78% 6.66B
Weighted average by Cap. +2.16%-3.22%-25.51%+64.49%

Financials

2022 2023
Net sales - 0.05 0.03 0.03 0.03 0.02 3.06 0.05 0.31 0.12 1.51 0.12 0.12 5.21
Net income -13.13M -9.27M -8.15M -7.56M -6.95M -887M -13.41M -90.04M -35.23M -436M -34.84M -34.07M -1.51B -7.43M -5.25M -4.62M -4.28M -3.94M -502M -7.6M -50.99M -19.95M -247M -19.73M -19.29M -853M
Net Debt -82.43K -58.21K -51.18K -47.45K -43.64K -5.57M -84.22K -565K -221K -2.74M -219K -214K -9.46M -953K -673K -592K -549K -505K -64.41M -974K -6.54M -2.56M -31.67M -2.53M -2.47M -109M
Logo Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments and other neurological conditions. The Company’s CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. It is also focused on developing the ICA for home use, for the remote monitoring of patient’s progress under treatment regimens and for general home healthcare check-ups. CognICA is available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East. Its subsidiaries include Cognetivity Ltd. and Cognetivity FZ-LLC.
Employees
-